Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|April 6, 2017
Limitations in Prior Authorizations for Specialty Drugs
Author(s)Lauren Santye, Assistant Editor
Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the impact of prior authorizations on specialty pharmacy.
Advertisement
Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the impact of prior authorizations on specialty pharmacy.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
5